You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
MSCI与Royalty Pharma合作推出生命科学指数系列
阿思达克 04-23 12:06
MSCI(MSCI.US)公布,与生物医药特许权买家及生物制药创新领域的领先投资者Royalty Pharma(RPRX.US)合作,将透过推出多个全新指数扩大MSCI的主题指数系列,以捕捉未来将颠覆生命科学、生物科技和医药行业的长期及前沿主题。

该系列指数计划於今年年底前推出,初期推出的指数将评估专注於提供与病毒学和肿瘤学相关创新疗法的企业的表现,Royalty Pharma将在多种病症、临床试验,及可能带来突破性医学治疗的转化治疗和技术上贡献专业知识,协助MSCI设计一个分类框架及制定指数的方法论。

MSCI主席兼行政总裁Henry Fernandez表示,新型肺炎疫情期间,生命科学公司对於塑造和发展医疗保健行业的重要性有目共睹,并在疾病预防和治疗方式的研发工作中担当了重要角色。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account